95 related articles for article (PubMed ID: 24953672)
1. Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.
Czarnecka AM; Oborska S; Rzepecki P; Szczylik C
Future Oncol; 2015; 11(1):17-26. PubMed ID: 24953672
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
Vrdoljak E; Rini B; Schmidinger M; Omrčen T; Torday L; Szczylik C; Sella A
Anticancer Drugs; 2013 Jun; 24(5):431-40. PubMed ID: 23511427
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
5. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Wong MK; Jarkowski A
Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Grandinetti CA; Goldspiel BR
Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
[TBL] [Abstract][Full Text] [Related]
7. Hypothyroidism during treatment with tyrosine kinase inhibitors.
Zygulska AL; Krzemieniecki K; Sowa-Staszczak A
Endokrynol Pol; 2012; 63(4):302-6. PubMed ID: 22933166
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
9. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
Pouessel D; Culine S
Eur Urol; 2008 Feb; 53(2):376-81. PubMed ID: 17825982
[TBL] [Abstract][Full Text] [Related]
10. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
Rini BI; Choueiri TK; Elson P; Khasawneh MK; Cotta C; Unnithan J; Wood L; Mekhail T; Garcia J; Dreicer R; Bukowski RM
Cancer; 2008 Sep; 113(6):1309-14. PubMed ID: 18618496
[TBL] [Abstract][Full Text] [Related]
12. Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses.
Shu M; Zai X; Zhang B; Wang R; Lin Z
PLoS One; 2016; 11(1):e0147048. PubMed ID: 26784451
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitor induced pancreatitis.
Sevin A; Chen A; Atkinson B
J Oncol Pharm Pract; 2013 Sep; 19(3):257-60. PubMed ID: 23034406
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
Tsuzuki T; Sassa N; Shimoyama Y; Morikawa T; Shiroki R; Kuroda M; Fukatsu A; Kuwahara K; Yoshino Y; Hattori R; Gotoh M
Histopathology; 2014 Mar; 64(4):484-93. PubMed ID: 24274732
[TBL] [Abstract][Full Text] [Related]
15. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
[TBL] [Abstract][Full Text] [Related]
16. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
Kitajima K; Takahashi S; Maeda T; Yoshikawa T; Ohno Y; Fujii M; Miyake H; Fujisawa M; Sugimura K
Eur J Radiol; 2012 Sep; 81(9):2060-5. PubMed ID: 21724350
[TBL] [Abstract][Full Text] [Related]
17. [Two cases of bowel perforation in patients with metastatic renal cancer treated with a molecularly targeted drug].
Kobayashi H; Ashikari A; Namitome R; Yagi Y; Kohno Y; Nishiyama T; Saito S
Nihon Hinyokika Gakkai Zasshi; 2012 Sep; 103(5):660-4. PubMed ID: 23342925
[TBL] [Abstract][Full Text] [Related]
18. [New drugs; sunitinib and sorafenib].
van Bronswijk H; Dubois EA; Osanto S; Cohen AF
Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2888-90. PubMed ID: 18257434
[TBL] [Abstract][Full Text] [Related]
19. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Eisen T; Sternberg CN; Robert C; Mulders P; Pyle L; Zbinden S; Izzedine H; Escudier B
J Natl Cancer Inst; 2012 Jan; 104(2):93-113. PubMed ID: 22235142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
